FDA has granted Pfizer’s (NYSE:PFE) investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, Breakthrough Therapy Designation. The designation covers active immunization of mothers during pregnancy to confer protection against invasive GBS disease in newborns and young infants. GBS disease can result in lifelong neurologic impairments or death, according to a 2019 article in…